The impact of carnosine on myosin for a possible intervention or prevention of systolic heart failure

Heart failure is a common but serious condition that affects approximately 5.7 million adults in the United States and costs the economy $30.7 billion each year. More specifically, systolic heart failure, otherwise known as heart failure with reduced ejection fraction (HFrEF), is the most common for...

Full description

Bibliographic Details
Main Author:	Kim, N.
Format:	Article
Language:	English
Published:	Royal St. George's College 2019-08-01
Series:	The Young Researcher
Subjects:	carnosine myosin myosin ATPase activity systolic heart failure contractile function Introduction Heart failure is a serious condition that affects approximately 5.7 million adults in the United States and costs the economy $30.7 billion each year (Division for Heart Disease and Stroke Prevention 2016). It occurs when the heart is not pumping enough blood to meet all of the body’s needs leading to a loss in vital functions and can affect both left and right sides of the heart (Nic 2012). The reasons for this reduced pumping of blood lie in cardiac enlargement or the enlargement of the heart and when heart muscles become too stiff to properly contract (McMullen and Jennings 2007). More specifically systolic heart failure is the most common form of heart failure and occurs when the muscle of the left ventricle of the heart loses its ability to contract preventing enough oxygen and blood from circulating throughout the body (“Heart Failure Signs and Symptoms which helps to classify the certain type of heart failure. Those possessing heart failure with reduced ejection fraction have 40% and below of the blood in the left ventricle of the heart pumped out to the rest of the body which is below the normal ejection fraction of more than 55% (Pai et. al 2017). Although a myriad of treatment options have emerged in recent years for the treatment of heart failure such as the use of Beta blockers or Angiotensin-converting enzyme (ACE) inhibitors there is yet to be an established and definite treatment for this condition (McConaghy & Smith 2004). This is due to the fact that even though current treatment options are effective to some extent in serving as a base-line treatment it is rather recommended by Becher Blankenberg and Westermann from the World Journal of Cardiology that future treatments focus on “augmentation of heart rate in order to increase cardiac output 2015). With this a promising approach to the development of an effective intervention of heart failure lies in a dipeptide that has been reasoned to increase cardiac contractility (Black et. al contractile function
Online Access:	http://www.theyoungresearcher.com/papers/kim.pdf

Internet

http://www.theyoungresearcher.com/papers/kim.pdf

The impact of carnosine on myosin for a possible intervention or prevention of systolic heart failure

Internet

Similar Items